Market Overview:
The global Hodgkin's lymphoma therapeutics market is expected to grow at a CAGR of 5.8% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of Hodgkin's lymphoma, rising awareness about available treatment options, and technological advancements in the field of cancer therapeutics. The global Hodgkin's lymphoma therapeutics market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into alkylating antineoplastic agents, antibiotic antineoplastic agents, antineoplastics vinca alkaloid agents, podophyllotoxin derivative antineoplastic agents, antimetabolite antineoplastic agents anthracycline anti-neoplastic agent and antimicrotubular anti-neoplastics. On the basis of application; hospitals accounted for majority share in 2017 owing to availability of advanced diagnostic and therapeutic facilities in these institutions.
Product Definition:
Hodgkin's lymphoma (HL) is a type of cancer that starts in the lymphatic system, which is part of the immune system. The lymphatic system helps fight infection and remove waste products from the body. Hodgkin's lymphoma is most common in young adults between 20 and 40 years old, but it can occur at any age.
Alkylating Antineoplastic Agents:
Alkylating antineoplastic agents are a group of drugs that act as alkylating agents and prevent the normal functioning of cells in the body. Alkylating antineoplastic agents include busulfan, chlorambucil, ifosfamide, procarbazine, and thiotepa.
Antibiotic Antineoplastic Agents:
Antibiotic antineoplastic agents are the drugs used to treat bacterial infections in the body. The antibiotics can be classified into two types: first generation and second generation. First generation includes penicillin, tetracycline, erythromycin and cephalosporin; while second-generation includes doxorubicin hydrochloride, bleomycin sulfate, vincristine sulfate and paclitaxel.
Application Insights:
The academic and research institutes segment held the largest revenue share of over 50% in 2017. This is attributed to presence of leading cancer centers that offer a wide range of treatment options for patients. For instance, The University Of Texas MD Anderson Cancer Center offers personalized care with world-class expertise for all stages of Hodgkin¢â‚¬â„¢s lymphoma along with other cancers at its Houston location. It has been named as one of the best cancer hospitals in U.S by U.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable government initiatives and increasing healthcare expenditure are some of the factors responsible for its growth. In 2014, according to a study conducted by IMS Health, Inc., it was estimated that U.S.
Asia Pacific Hodgkin's lymphoma therapeutics market is anticipated to witness lucrative growth over the forecast period owing to rising disposable income coupled with improving access & infrastructure development in emerging countries such as China & India which would subsequently drive this regional segment during the forecast period from 2018-2030 The key companies operating in this region include Bupropion Hydrochloride (BH) Ltd.; Cipla Inc.; Eisai Co., Ltd; Gilead Sciences, Inc.; Johnson & Johnson Services India Pvt.
Growth Factors:
- Increasing incidence of Hodgkin's lymphoma
- Growing awareness about the disease and its treatment options
- Rising demand for better and more effective therapies for Hodgkin's lymphoma
- Availability of government funding for research on new Hodgkin's lymphoma therapies
- Technological advancements in the field of cancer therapy
Scope Of The Report
Report Attributes
Report Details
Report Title
Hodgkin's Lymphoma Therapeutics Market Research Report
By Type
Alkylating Antineoplastic Agents, Antibiotic Antineoplastic Agents, Antineoplastics Vinca Alkaloid Agents, Podophyllotoxin Derivative Antineoplastic Agents, Antimetabolite Antineoplastic Agents, Anthracycline Antineoplastic Agents, Antimicrotubular Antineoplastics, Corticosteroids
By Application
Hospitals, Academic and Research Institutes
By Companies
Bristol Myers Squibb, F. Hoffmann-La Roche, Merck, Pfizer
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
219
Number of Tables & Figures
154
Customization Available
Yes, the report can be customized as per your need.
Global Hodgkin's Lymphoma Therapeutics Market Report Segments:
The global Hodgkin's Lymphoma Therapeutics market is segmented on the basis of:
Types
Alkylating Antineoplastic Agents, Antibiotic Antineoplastic Agents, Antineoplastics Vinca Alkaloid Agents, Podophyllotoxin Derivative Antineoplastic Agents, Antimetabolite Antineoplastic Agents, Anthracycline Antineoplastic Agents, Antimicrotubular Antineoplastics, Corticosteroids
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Academic and Research Institutes
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol Myers Squibb
- F. Hoffmann-La Roche
- Merck
- Pfizer
Highlights of The Hodgkin's Lymphoma Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Alkylating Antineoplastic Agents
- Antibiotic Antineoplastic Agents
- Antineoplastics Vinca Alkaloid Agents
- Podophyllotoxin Derivative Antineoplastic Agents
- Antimetabolite Antineoplastic Agents
- Anthracycline Antineoplastic Agents
- Antimicrotubular Antineoplastics
- Corticosteroids
- By Application:
- Hospitals
- Academic and Research Institutes
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Hodgkin's Lymphoma Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Hodgkin's lymphoma therapeutics is a group of drugs used to treat Hodgkin's lymphoma. These drugs work by stopping the growth of cancer cells.
Some of the key players operating in the hodgkin's lymphoma therapeutics market are Bristol Myers Squibb, F. Hoffmann-La Roche, Merck, Pfizer.
The hodgkin's lymphoma therapeutics market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Hodgkin's Lymphoma Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Hodgkin's Lymphoma Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Hodgkin's Lymphoma Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Hodgkin's Lymphoma Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Hodgkin's Lymphoma Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Hodgkin's Lymphoma Therapeutics Market Size and Y-o-Y Growth
4.5.2 Hodgkin's Lymphoma Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Hodgkin's Lymphoma Therapeutics Market Size Forecast by Type
5.2.1 Alkylating Antineoplastic Agents
5.2.2 Antibiotic Antineoplastic Agents
5.2.3 Antineoplastics Vinca Alkaloid Agents
5.2.4 Podophyllotoxin Derivative Antineoplastic Agents
5.2.5 Antimetabolite Antineoplastic Agents
5.2.6 Anthracycline Antineoplastic Agents
5.2.7 Antimicrotubular Antineoplastics
5.2.8 Corticosteroids
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Hodgkin's Lymphoma Therapeutics Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Academic and Research Institutes
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Hodgkin's Lymphoma Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Hodgkin's Lymphoma Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Hodgkin's Lymphoma Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Hodgkin's Lymphoma Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Hodgkin's Lymphoma Therapeutics Market Size Forecast by Type
9.6.1 Alkylating Antineoplastic Agents
9.6.2 Antibiotic Antineoplastic Agents
9.6.3 Antineoplastics Vinca Alkaloid Agents
9.6.4 Podophyllotoxin Derivative Antineoplastic Agents
9.6.5 Antimetabolite Antineoplastic Agents
9.6.6 Anthracycline Antineoplastic Agents
9.6.7 Antimicrotubular Antineoplastics
9.6.8 Corticosteroids
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Hodgkin's Lymphoma Therapeutics Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Academic and Research Institutes
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Hodgkin's Lymphoma Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Hodgkin's Lymphoma Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Hodgkin's Lymphoma Therapeutics Market Size Forecast by Type
10.6.1 Alkylating Antineoplastic Agents
10.6.2 Antibiotic Antineoplastic Agents
10.6.3 Antineoplastics Vinca Alkaloid Agents
10.6.4 Podophyllotoxin Derivative Antineoplastic Agents
10.6.5 Antimetabolite Antineoplastic Agents
10.6.6 Anthracycline Antineoplastic Agents
10.6.7 Antimicrotubular Antineoplastics
10.6.8 Corticosteroids
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Hodgkin's Lymphoma Therapeutics Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Academic and Research Institutes
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Hodgkin's Lymphoma Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Hodgkin's Lymphoma Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Hodgkin's Lymphoma Therapeutics Market Size Forecast by Type
11.6.1 Alkylating Antineoplastic Agents
11.6.2 Antibiotic Antineoplastic Agents
11.6.3 Antineoplastics Vinca Alkaloid Agents
11.6.4 Podophyllotoxin Derivative Antineoplastic Agents
11.6.5 Antimetabolite Antineoplastic Agents
11.6.6 Anthracycline Antineoplastic Agents
11.6.7 Antimicrotubular Antineoplastics
11.6.8 Corticosteroids
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Hodgkin's Lymphoma Therapeutics Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Academic and Research Institutes
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Hodgkin's Lymphoma Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Hodgkin's Lymphoma Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Hodgkin's Lymphoma Therapeutics Market Size Forecast by Type
12.6.1 Alkylating Antineoplastic Agents
12.6.2 Antibiotic Antineoplastic Agents
12.6.3 Antineoplastics Vinca Alkaloid Agents
12.6.4 Podophyllotoxin Derivative Antineoplastic Agents
12.6.5 Antimetabolite Antineoplastic Agents
12.6.6 Anthracycline Antineoplastic Agents
12.6.7 Antimicrotubular Antineoplastics
12.6.8 Corticosteroids
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Hodgkin's Lymphoma Therapeutics Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Academic and Research Institutes
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Hodgkin's Lymphoma Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Hodgkin's Lymphoma Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Hodgkin's Lymphoma Therapeutics Market Size Forecast by Type
13.6.1 Alkylating Antineoplastic Agents
13.6.2 Antibiotic Antineoplastic Agents
13.6.3 Antineoplastics Vinca Alkaloid Agents
13.6.4 Podophyllotoxin Derivative Antineoplastic Agents
13.6.5 Antimetabolite Antineoplastic Agents
13.6.6 Anthracycline Antineoplastic Agents
13.6.7 Antimicrotubular Antineoplastics
13.6.8 Corticosteroids
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Hodgkin's Lymphoma Therapeutics Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Academic and Research Institutes
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Hodgkin's Lymphoma Therapeutics Market: Competitive Dashboard
14.2 Global Hodgkin's Lymphoma Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bristol Myers Squibb
14.3.2 F. Hoffmann-La Roche
14.3.3 Merck
14.3.4 Pfizer
